The IL-1β antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure
N Harouki, L Nicol, I Remy-Jouet, JP Henry… - Basic to Translational …, 2017 - jacc.org
N Harouki, L Nicol, I Remy-Jouet, JP Henry, A Dumesnil, A Lejeune, S Renet, F Golding…
Basic to Translational Science, 2017•jacc.orgThis study reports preclinical data showing that the interleukin (IL)-1β modulation is a new
promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic
Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial
infarction, administration of the IL-1β antibody gevokizumab improves 'surrogate'markers of
survival (ie, left ventricular remodeling, hemodynamics, and function as well as coronary
function). However, whether IL-1β modulation per se or in combination with standard …
promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic
Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial
infarction, administration of the IL-1β antibody gevokizumab improves 'surrogate'markers of
survival (ie, left ventricular remodeling, hemodynamics, and function as well as coronary
function). However, whether IL-1β modulation per se or in combination with standard …
Summary
This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves ‘surrogate’ markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.
jacc.org
